Drug updated on 11/17/2023

Dosage FormInjection (subcutaneous): 160 mg/mL in a single-dose prefilled syringe or single-dose prefilled autoinjector
Drug ClassMonoclonal antibody
Ongoing and Completed


  • Bimzelx (bimekizumab injection) is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adult patients who are candidates for systemic therapy or phototherapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Bimzelx (bimekizumab) Prescribing Information.2023FDA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines